Nucleai Appoints Vikas Ahuja as Vice President of Strategic Partnerships to Enable Diagnostic Deployment and Commercialization at Scale
May 16 2024 - 7:00AM
Business Wire
Vikas Ahuja brings over 20 years of strategic
business experience in the life sciences industry from Quest
Diagnostics, Ambry Genetics and Mallinckrodt Pharmaceuticals
Nucleai, a spatial AI biomarker company that deciphers cellular
conversations and maps cellular interactions within tissue samples
to predict therapeutic outcomes, announced today the expansion of
its executive leadership team with the appointment of Vikas Ahuja
as Vice President of Strategic Partnerships. With over 20 years of
experience in life sciences, Ahuja will be responsible for building
an ecosystem of partners—including diagnostic companies, contract
research organizations (CROs), assay and instrument vendors, and
software companies—that will enable Nucleai’s AI platform to be
deployed at scale for late-stage clinical trials and diagnostic
applications.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240516792275/en/
Pictured: Vikas Ahuja, Vice President of
Strategic Partnerships, Nucleai (Photo: Business Wire)
"Vikas has a wealth of experience and knowledge in business
development across various sectors within the life sciences
industry and is a perfect addition to our team,” said Avi Veidman,
CEO of Nucleai. “Our AI spatial technology is currently used in an
active clinical trial to aid patient selection. We’re seeing an
increasing need for AI spatial biomarkers to support the rapidly
growing pipeline of next-generation treatments, including
antibody-drug conjugates, multi-specifics, and novel checkpoint
inhibitors. Vikas’ proven track record of fostering strategic
alliances and driving global growth initiatives speaks volumes
about his expertise in building partnerships to scale the
deployment of novel diagnostics. We are thrilled to welcome him to
Nucleai, where his insights and leadership will accompany our
mission to power the next generation of precision therapeutics with
AI-driven spatial biomarkers and diagnostics.”
Before joining Nucleai, Ahuja held a leadership role as Vice
President of Business Development & Strategy at Ambry Genetics,
where he spearheaded corporate strategy, M&A activities, and
licensing initiatives, and oversaw International business segments.
He also led the establishment of international partnerships,
strategically forging alliances across regions like Latin America,
the Middle East, Southeast Asia, China, and Australia at
Mallinckrodt Pharmaceuticals.
"This role presents a tremendous opportunity to leverage my
experience in building impactful collaborations across the life
sciences sector,” said Ahuja. “The recent partnership with GoPath
Diagnostics is a prime example of how strategic alliances can
advance our mission of transforming patient care through advanced
AI-driven spatial biomarkers. I look forward to fostering similar
partnerships to enhance our relationships with large commercial and
diagnostic companies, propelling our innovative platform to new
heights and ultimately improving patient outcomes."
Ahuja earned his MBA from The Wharton School of the University
of Pennsylvania and his MS in Chemical Engineering from Imperial
College, London.
About Nucleai
Nucleai is the leading AI-powered spatial biomarker company,
driving innovation at the intersection of technology and
healthcare. Leveraging military intelligence-grade geospatial
analytical methods, it intercepts, interprets, and analyzes complex
cellular conversations and spatially oriented interactions within
tissue samples, translating them into actionable insights.
Nucleai’s platform empowers pathologists and researchers with an
AI-powered data-rich action plan, paving the way for more informed
decisions in the development of bi-specifics, antibody-drug
conjugates (ADCs), and immunotherapy. Nucleai's investors include
Section 32, Sanofi, Vertex Ventures, M Ventures, and Debiopharm
Innovation Fund. It is headquartered in Israel and Chicago. For
more information, please visit www.nucleai.ai.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240516792275/en/
Consort Partners for Nucleai nucleai@consortpartners.com